key: cord-0926633-ngzra7re
authors: Seligmann, Hervé
title: Balanced evaluation of preliminary data on a candidate COVID-19 hydroxychloroquine treatment
date: 2021-03-10
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2021.106292
sha: f5c3cf654d688d56233acb4d305fc490cd0bc9ae
doc_id: 926633
cord_uid: ngzra7re

nan

outcome substituting clinical outcome are shortcomings inherent to any methodologically similar study. However, I do raise a serious additional methodological caveat inherent to qualitative PCRbased diagnostics, namely: high rates of false-negative PCRs. Apparent inconsistencies between Figures 1 and 2 in the Gautret et al. paper [1] are another concern. However, a complete evidence meta-analysis approach convinced this author, who was previously highly suspicious of the findings of the Gautret et al. paper [1] , that the proposed treatment is a viable candidate for unbiased large-scale tests. PCR contamination causes false-positives, whilst poor-quality samples, genetic variability or reagent issues cause false-negatives [4] . Data from Gautret et al. include false-negatives: their supplementary table showed that among 45 tests on days succeeding a negative PCR, nine (20%) were positive the next day [1] . This was probably a result of samples collection by nasopharyngeal swabs, their preparation for PCR and PCR-related artefacts. Gautret et al. noted the possibility of a false-positive when a patient received the hydroxychloroquine and azithromycin combination, tested negative on day 6 post-inclusion, then tested positive at low titre on day 8 post-inclusion. However, they did not discuss the possible influence of false-negative results in their study. Falsenegative results present the risk of release of individuals believed to be cured but potentially still infectious. Unbiased authors and critics should note this.

In the Gautret et al. paper, data for controls in the Figures seem consistent; however, visually notable differences occurred each day for the hydroxychloroquine-treated sample. This raises suspicions regarding the results. Analyses that integrate all available evidence produce more reliable results. A simple statistical procedure that integrates differences between control and hydroxychloroquinetreated samples, and accounts for time, can be applied. Figure 1 is an alternative presentation of the results from Gautret et al. [1] : percentages of negative PCRs among tested control patients are subtracted from percentages of hydroxychloroquine-treated patients for each day, and plotted vs. days since treatment beginning. The differences in percentages gradually increase ( r = 0.80331, one tailed P = 0.015). As described by Lichtenstein [4] , the prevalence of negative PCRs among these samples for any specific day never differs (Fisher's exact test, P > 0.05). This analysis detects a cumulating systematic gradual effect; it is a powerful tool to detect weak phenomena, or strong ones in small samples.

Despite all of the shortcomings of the Gautret et al. study [1] , the findings seem consistent with the observation that countrybased comparisons of COVID-19 deaths rates are lower in countries with widespread early hydroxychloroquine use [5] . The shortcomings of data and analyses in the Gautret et al. paper are obvious and understandable during an acute global crisis. Rather than focusing on more trivial methodological failings, critics should have noted the possibility of false-negative PCRs and the clinical risks that these may present. Level-headed unbiased evidence evaluation justifies that the proposed treatment be considered as a viable option for tests. Unfortunately, unbiased scientific evaluation of all the evidence at hand has become increasingly rare, with and without the pandemic. The current crisis emphasises the existential need for this mental capacity, combined with honest professional ethics, for authors and critics, with the latter deserving harsher criticism than the former. 

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Statistical review of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial

Are Coronavirus tests accurate?

Early treatment with hydroxychloroquine: a country-based analysis

None.

Not required.'